Kakao Ventures seeds a four-month-old startup that estimates the angiography frames the X-ray skipped

Corologic's premise is that the dose comes from the number of X-ray images captured, so the route to less of it is to capture fewer and generate the rest ^[6]. AngioFilm reads the position and movement of vessels and devices in the frames on either side of a gap, estimates the intermediate view, and writes a new frame in real time ^[5]. It runs on hardware inside the hospital, alongside angiography machines the hospital already owns ^[7]. The company did not disclose how much it raised, and the announcement does not include a measured dose reduction ^[5].

Kakao Ventures put the investment case on the software's independence from hardware vendors. "Because it is a standalone solution that is not tied to any particular equipment manufacturer, we see potential for expansion into global markets," said Jung Joo-yeon, a senior investment manager at the firm ^[11]. Independence is also a distribution problem. A vendor with an installed base gets a sale every time a hospital replaces a machine; an add-on has to be sold one procedure room at a time, to hospitals whose capital budget already went on the fluoroscopy suite ^[7].

The dates sit close together. The team, led by Professor Kang Si-hyuk of the cardiology division at Seoul National University Bundang Hospital, incorporated in May ^[3]. That same month it presented research findings and demonstrated the product at EuroPCR in Paris ^[8]. In August it completed a medical device filing with Korea's Ministry of Food and Drug Safety ^[9], and the seed round was announced on 15 September ^[1]. So the company was about four months old when the round closed ^[1], and the Paris demonstration falls in the founding month, which puts the underlying work at the hospital before the corporate entity existed ^[2]. SNU Holdings invested alongside Kakao Ventures ^[1].

I'd expect the validation, not the software, to set the timetable here. The stated use is letting staff follow vessel movement and the course of the procedure without interruption ^[6], and multicenter data has to show that an estimated frame supports that during a live intervention ^[2]. If it does, dose reduction becomes a software line item a hospital can justify on staff safety grounds. If interpolation loses a device tip at the wrong moment, the four remaining approval items never get tested ^[10].

The exposure Corologic is selling against is occupational as much as patient-side: the procedures are performed while viewing X-ray fluoroscopic images, and the staff take part in them repeatedly ^[4]. "In cardiovascular intervention, medical staff as well as patients are continuously exposed to radiation, so this is an area that needs a technological solution to improve safety," said Hwang Kyung-rae, chief executive of Corologic ^[13].